| Original language | English (US) |
|---|---|
| Pages (from-to) | 1565-1566 |
| Number of pages | 2 |
| Journal | Journal of Allergy and Clinical Immunology: In Practice |
| Volume | 8 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2020 |
ASJC Scopus subject areas
- Immunology and Allergy
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
The Rationale for Multidisciplinary Management of Chronic Rhinosinusitis with Nasal Polyposis. / Lal, Devyani; Borish, Larry; Detwiller, Kara Y. et al.
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 8, No. 5, 05.2020, p. 1565-1566.Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - The Rationale for Multidisciplinary Management of Chronic Rhinosinusitis with Nasal Polyposis
AU - Lal, Devyani
AU - Borish, Larry
AU - Detwiller, Kara Y.
AU - Gray, Stacey T.
AU - Joshi, Shyam
AU - Kern, Robert C.
AU - Laidlaw, Tanya M.
AU - Marino, Michael J.
AU - Payne, Spencer C.
AU - Peters, Anju T.
AU - Soler, Zachary M.
AU - Rank, Matthew A.
N1 - Funding Information: Conflicts of interest: L. Borish reports grant support to his institution from the National Institutes of Health , Regeneron , GlaxoSmithKline (GSK), Genentech , and Incyte ; and is serving on an advisory board for Sanofi/Regeneron. R. C. Kern reports serving as a consultant to Lyra Therapeutics, Sanofi/Regeneron, Astellas, Genentech, and Neurent. T. M. Laidlaw reports serving as a consultant to Vertex, Regeneron, and GSK. S. C. Payne reports grant support to his institution from AstraZeneca and Cumberland Pharmaceuticals and consulting for Cook Medical. A. T. Peters reports research grants from her institution to AstraZeneca and Optinose and consulting for Sanofi Regeneron, AstraZeneca, and Optinose. Z. M. Soler reports consulting for Olympus, Novartis, Regeneron, Optinose, and Healthy Humming. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Conflicts of interest: L. Borish reports grant support to his institution from the National Institutes of Health, Regeneron, GlaxoSmithKline (GSK), Genentech, and Incyte; and is serving on an advisory board for Sanofi/Regeneron. R. C. Kern reports serving as a consultant to Lyra Therapeutics, Sanofi/Regeneron, Astellas, Genentech, and Neurent. T. M. Laidlaw reports serving as a consultant to Vertex, Regeneron, and GSK. S. C. Payne reports grant support to his institution from AstraZeneca and Cumberland Pharmaceuticals and consulting for Cook Medical. A. T. Peters reports research grants from her institution to AstraZeneca and Optinose and consulting for Sanofi Regeneron, AstraZeneca, and Optinose. Z. M. Soler reports consulting for Olympus, Novartis, Regeneron, Optinose, and Healthy Humming. The rest of the authors declare that they have no relevant conflicts of interest. This work did not receive any specific grant funding from agencies in the public, commercial, or not-for-profit sectors.
PY - 2020/5
Y1 - 2020/5
UR - http://www.scopus.com/inward/record.url?scp=85081935996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081935996&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.03.001
DO - 10.1016/j.jaip.2020.03.001
M3 - Editorial
C2 - 32173370
AN - SCOPUS:85081935996
VL - 8
SP - 1565
EP - 1566
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
SN - 2213-2198
IS - 5
ER -